376 related articles for article (PubMed ID: 28485176)
1. The role of IL-17 in the treatment of psoriatic arthritis.
Lubrano E; Perrotta FM
Expert Rev Clin Immunol; 2017 Aug; 13(8):815-821. PubMed ID: 28485176
[TBL] [Abstract][Full Text] [Related]
2. Use of brodalumab for the treatment of psoriasis and psoriatic arthritis.
Kivelevitch DN; Menter A
Immunotherapy; 2015; 7(4):323-33. PubMed ID: 25917624
[TBL] [Abstract][Full Text] [Related]
3. Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review.
Thibodaux RJ; Triche MW; Espinoza LR
Expert Opin Biol Ther; 2018 Jul; 18(7):821-827. PubMed ID: 29949399
[TBL] [Abstract][Full Text] [Related]
4. The role of IL 23 in the treatment of psoriasis.
Puig L
Expert Rev Clin Immunol; 2017 Jun; 13(6):525-534. PubMed ID: 28165883
[TBL] [Abstract][Full Text] [Related]
5. Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis.
Lubrano E; Perrotta FM
Drugs; 2016 Apr; 76(6):663-73. PubMed ID: 26957495
[TBL] [Abstract][Full Text] [Related]
6. Th17 Inhibitors in Active Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.
Naik GS; Ming WK; Magodoro IM; Akinwunmi B; Dar S; Poulsen HE; Kristensen LE; Ellervik C
Dermatology; 2017; 233(5):366-377. PubMed ID: 29258093
[TBL] [Abstract][Full Text] [Related]
7. Role of IL-17 in psoriasis and psoriatic arthritis.
Raychaudhuri SP
Clin Rev Allergy Immunol; 2013 Apr; 44(2):183-93. PubMed ID: 22362575
[TBL] [Abstract][Full Text] [Related]
8. Novel approaches to biological therapy for psoriatic arthritis.
Boyd T; Kavanaugh A
Expert Opin Biol Ther; 2016; 16(2):173-86. PubMed ID: 26572089
[TBL] [Abstract][Full Text] [Related]
9. A review of ixekizumab in the treatment of psoriatic arthritis.
O'Rielly DD; Rahman P
Expert Rev Clin Immunol; 2018 Dec; 14(12):993-1002. PubMed ID: 30360663
[TBL] [Abstract][Full Text] [Related]
10. Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis.
Toussirot E
Expert Opin Biol Ther; 2018 Jan; 18(1):101-107. PubMed ID: 29187009
[TBL] [Abstract][Full Text] [Related]
11. Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis.
Raychaudhuri SK; Saxena A; Raychaudhuri SP
Clin Rheumatol; 2015 Jun; 34(6):1019-23. PubMed ID: 25939522
[TBL] [Abstract][Full Text] [Related]
12. Treatment of psoriatic arthritis with traditional DMARD's and novel therapies: approaches and recommendations.
Maharaj AB; Chandran V
Expert Rev Clin Immunol; 2017 Apr; 13(4):319-331. PubMed ID: 27826996
[TBL] [Abstract][Full Text] [Related]
13. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.
Elyoussfi S; Thomas BJ; Ciurtin C
Rheumatol Int; 2016 May; 36(5):603-12. PubMed ID: 26892034
[TBL] [Abstract][Full Text] [Related]
14. Ustekinumab: The "New Kid on the Block" in the Treatment of Psoriatic Arthritis.
Torres T; Faria R
Drug Dev Res; 2015 Dec; 76(8):428-31. PubMed ID: 26372543
[TBL] [Abstract][Full Text] [Related]
15. Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis.
Alunno A; Carubbi F; Cafaro G; Pucci G; Battista F; Bartoloni E; Giacomelli R; Schillaci G; Gerli R
Expert Opin Biol Ther; 2015; 15(12):1727-37. PubMed ID: 26653110
[TBL] [Abstract][Full Text] [Related]
16. IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications.
von Stebut E; Boehncke WH; Ghoreschi K; Gori T; Kaya Z; Thaci D; Schäffler A
Front Immunol; 2019; 10():3096. PubMed ID: 32010143
[TBL] [Abstract][Full Text] [Related]
17. Apremilast for the treatment of psoriatic arthritis.
Souto A; Gómez-Reino JJ
Expert Rev Clin Immunol; 2015; 11(12):1281-90. PubMed ID: 26503917
[TBL] [Abstract][Full Text] [Related]
18. Biological agents in psoriatic arthritis.
Kocijan R; Muschitz C; Rech J
Wien Med Wochenschr; 2015 Jan; 165(1-2):36-9. PubMed ID: 25205184
[TBL] [Abstract][Full Text] [Related]
19. Abatacept for the treatment of psoriatic arthritis.
Lubrano E; Scriffignano S; Perrotta FM
Expert Rev Clin Immunol; 2018 Nov; 14(11):899-905. PubMed ID: 30246575
[TBL] [Abstract][Full Text] [Related]
20. Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritis.
Ooms A; Al-Mossawi H; Bennett L; Bogale M; Bowness P; Francis A; Goodyear C; Kirkham BW; Lalnunhlimi S; McInnes IB; Richards D; Siebert S; Taams LS; Tulunay Virlan A; Yager N; Coates LC
BMJ Open; 2023 Sep; 13(9):e078539. PubMed ID: 37770264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
